ArticleAntimicrobial agents and chemotherapy2019
Results from a Prospective
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The mecillinam resistome inAntimicrobial agents and chemotherapy · 2026Article
- Similarities in the consumption trajectory of antibacterial drugs in the outpatient care sector in Germany from 1986 to 2022: identification of shared patterns, correlation analysis of prescribed defined daily dose and assessment of underlying influences.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- New Perspectives on Antimicrobial Agents: Pivmecillinam.Antimicrobial agents and chemotherapy · 2025Review
- Performance of disc diffusion and four commercially available MIC tests to determine mecillinam susceptibility on carbapenemase-producing Enterobacterales.Journal of clinical microbiology · 2025Article
- Costs are a major driver of antibacterial drug prescriptions in Germany: market analysis from 1985 to 2022.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens.Open forum infectious diseases · 2024Review
- Activity of mecillinam against carbapenem-resistant Enterobacterales.The Journal of antimicrobial chemotherapy · 2022Article
- Article
- Resistance to Mecillinam and Nine Other Antibiotics for Oral Use inAntibiotics (Basel, Switzerland) · 2022Article
- US-Focused Conceptual Health Care Decision-Analytic Models Examining the Value of Pivmecillinam Relative to Current Standard-of-Care Agents Among Adult Patients With Uncomplicated Urinary Tract Infections due to Enterobacterales.Open forum infectious diseases · 2021Article
- The Prevalence and Characterization of Fecal Extended-Spectrum-Beta-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2021Article
- Article
- Susceptibility of Clinical Enterobacterales Isolates With Common and Rare Carbapenemases to Mecillinam.Frontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The activity of mecillinam (amdinocillin) was assessed in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.